info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
United States Flag  US: +1-315-636-4233    United Kingdom Flag  UK: +44-162-237-0614    Indian Flag  IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
Home » Press Releases » Global Breast Cancer Liquid Biopsy Market (2020-2030) will grow to USD 604.71 Mn by 2030 with a CAGR of 19.2%

Global Breast Cancer Liquid Biopsy Market (2020-2030) will grow to USD 604.71 Mn by 2030 with a CAGR of 19.2%


Published Date: Apr-2022 | Report Format:Electronic (PDF)

The report about 'Global Breast Cancer Liquid Biopsy Market' By Indicators or Circulating Biomarkers(Circulating Tumour Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles, Others).Based on End-users(Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories). By Region (North America, Europe, Asia-Pacific, Middle-East and Africa, South America). With a market size of USD 104.42 Mn in 2020, the Global Breast Cancer Liquid Biopsy Market Size will grow to USD 604.71 Mn by 2030 with a CAGR of 19.2%.

 

To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/breast-cancer-liquid-biopsy-market-

 

Key Factors that are expediting the Market growth

Key factors that promote the growth of the breast cancer liquid biopsy market are the rise in prevalence of breast cancer, technological advancements in breast cancer, use of liquid biopsy instruments, increase in preference for non-invasive procedures, advantages of over solid tumour biopsy, and increase in patient awareness towards minimally invasive breast cancer liquid biopsy procedures. 

 

Based on Indicators, The Circulating Cell-free DNA (cfDNA) Segment is predicted to hold a Major Market Share.

The Circulating Cell-free DNA (cfDNA) Segment continued to lead the market due to its ability to detect emerging genomic alterations associated with drug resistance, the potential to clarify cancer prognosis and diagnose cancer recurrence or progression and the ability to detect emerging genomic alterations associated with drug resistance are attributed to this Breast Cancer liquid biopsy screening market.

 

Based on end-user, The Reference Laboratories Segment is the most significant global breast cancer liquid biopsy market. 

 Reference laboratories are extensive, well-equipped laboratories with genetic testing facilities that receive many samples from hospitals and private practitioners.

 

NORTH AMERICA SIGNIFICANTLY DOMINATED THE LIQUID BIOPSY MARKET IN 2020

Among the regions, North America dominated the global liquid biopsy market in 2020. This dominance is attributed to the increased healthcare expenditure, easy accessibility to technologically advanced instruments, increased awareness of different types of cancer, and advanced diagnostic technologies. Furthermore, the rising cancer occurrence in the United States has exponentially boosted the liquid biopsy industry. 

 

The American Cancer Society (2020) estimates that there will be 1.8 million new cancer diagnoses and more than 6 lakh deaths in the United States. As a result, the liquid biopsy market in North America has been driven by an increase in cancer diagnoses among the US population. Other factors include easy access to technologically advanced instruments, developed healthcare systems in the United States and Canada, and many leading national clinical laboratories.

 

Soon, The Asia Pacific is most likely to be the most profitable market. The market is growing due to rising government investments in establishing advanced hospitals and the growing penetration of multiple diagnostic laboratories in the region. Moreover, the increasing incidences of cancer and the presence of a colossal population are boosting the need to develop technologically advanced healthcare units, spurring the demand for liquid biopsy in the Asia Pacific market. 

 

 IMPORTANT MARKET PLAYERS:

Some of the pivotal players in the Global Breast Cancer Liquid Biopsy Market field

include Johnson & Johnson (Janssen Diagnostics), F. Hoffmann-La Roche Ltd, Qiagen, Janssen, Diagnostics, Guardant Health Inc., Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, Fluxion Biosciences Inc., Biodesix, Illumina Inc., Bio-Rad Laboratories, Biocept Inc,)

 

Recent Developments

  • In April 2022,Inivata, a leader in liquid biopsy, announced the publishing of fresh data supporting its RaDaR liquid biopsy test in patients with early-stage non-small-cell lung cancer (NSCLC). In addition, the data from the Lung cancer. A circulating tumour DNA (LUCID) study has been published in the Annals of Oncology.
  • In January 2021, HiberCell & Biodesix signed a deal to continue developing anenzyme-linked immunosorbent assay (ELISA) as a companion diagnostic test.
  • In December 2020, Biocept Inc. announced the findings of a prospective study, demonstrating that the Target Selector (a sensitive blood-based testing tool) was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer.
  • In August 2020, Personalis, Inc. released the NeXT Liquid Biopsy, a high-performance, an exome-scale tumour-profiling platform that uses blood samples from advanced-stage solid tumour cancer patients.

 

Choose License Type



$0
$0
$0
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: (+1) 315-636-4233
  • UK: (+44) 1622-370-614
  • IN: (+91) 826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved